Atossa Therapeutics Newsroom

Atossa Therapeutics Analyst Ratings

BenzingaJun 28 11:13 ET

Atossa Therapeutics Analyst Ratings

BenzingaJun 20 13:27 ET

Atossa Therapeutics Analyst Ratings

BenzingaJun 6 13:10 ET

Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating

TipRanksMay 14 13:40 ET

Atossa Therapeutics Analyst Ratings

BenzingaApr 16 11:04 ET

Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)

TipRanksApr 3 15:25 ET

Atossa Therapeutics Analyst Ratings

BenzingaApr 2 08:37 ET

Atossa Therapeutics Analyst Ratings

BenzingaFeb 12 07:36 ET

Atossa Therapeutics' Strong Financial Position and Promising Clinical Trials Drive Buy Rating: A Focus on Oral Endoxifen Breast Cancer Treatment

TipRanksNov 15, 2023 12:36 ET

Atossa Stock Jumps 16% in Wake of Cantor Overweight Rating

Seeking AlphaSep 8, 2023 12:29 ET

Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5

BenzingaSep 8, 2023 08:16 ET

Atossa Therapeutics Analyst Ratings

BenzingaSep 8, 2023 08:15 ET

Analysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR) and Atossa Therapeutics (ATOS)

TipRanksAug 15, 2023 13:40 ET

Maxim Group Keeps Their Buy Rating on Atossa Therapeutics (ATOS)

TipRanksJul 11, 2023 13:45 ET

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS) and Karuna Therapeutics (KRTX)

TipRanksMar 22, 2023 08:23 ET

Maxim Group Sticks to Its Buy Rating for Atossa Therapeutics (ATOS)

TipRanksFeb 24, 2023 13:20 ET

Analysts Offer Insights on Healthcare Companies: Omeros (OMER), Atossa Therapeutics (ATOS) and PDS Biotechnology (PDSB)

TipRanksAug 10, 2022 08:20 ET